Literature DB >> 20219622

Treatment strategies and clinical trial design in ADPKD.

Vicente E Torres1.   

Abstract

More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes. 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219622      PMCID: PMC4127876          DOI: 10.1053/j.ackd.2010.01.006

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  83 in total

1.  Hypertension and renal injury in experimental polycystic kidney disease.

Authors:  T M Kennefick; M A Al-Nimri; T T Oyama; M M Thompson; F J Kelly; J G Chapman; S Anderson
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

2.  Functional correction of renal defects in a mouse model for ARPKD through expression of the cloned wild-type Tg737 cDNA.

Authors:  B K Yoder; W G Richards; C Sommardahl; W E Sweeney; E J Michaud; J E Wilkinson; E D Avner; R P Woychik
Journal:  Kidney Int       Date:  1996-10       Impact factor: 10.612

3.  Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.

Authors:  Piero Ruggenenti; Andrea Remuzzi; Patrizia Ondei; Giorgio Fasolini; Luca Antiga; Bogdan Ene-Iordache; Giuseppe Remuzzi; Franklin H Epstein
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

4.  Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors.

Authors:  Hiroaki Ogata; Eberhard Ritz; Giulio Odoni; Kerstin Amann; Stephan R Orth
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

5.  A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype.

Authors:  L Pritchard; J A Sloane-Stanley; J A Sharpe; R Aspinwall; W Lu; V Buckle; L Strmecki; D Walker; C J Ward; C E Alpers; J Zhou; W G Wood; P C Harris
Journal:  Hum Mol Genet       Date:  2000-11-01       Impact factor: 6.150

6.  Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1.

Authors:  Si-Tse Jiang; Yuan-Yow Chiou; Ellian Wang; Hsiu-Kuan Lin; Yuan-Ta Lin; Ying-Chih Chi; Chi-Kuang Leo Wang; Ming-Jer Tang; Hung Li
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

7.  Polycystin-2 is an intracellular calcium release channel.

Authors:  Peter Koulen; Yiqiang Cai; Lin Geng; Yoshiko Maeda; Sayoko Nishimura; Ralph Witzgall; Barbara E Ehrlich; Stefan Somlo
Journal:  Nat Cell Biol       Date:  2002-03       Impact factor: 28.824

8.  Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.

Authors:  Tamio Yamaguchi; Scott J Hempson; Gail A Reif; Anne-Marie Hedge; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2005-11-30       Impact factor: 10.121

9.  Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling.

Authors:  Yun Li; Jerry M Wright; Feng Qian; Gregory G Germino; William B Guggino
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

10.  Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; J A Breyer; G J Beck; V W Dennis; J A Hartman; D Roth; T I Steinman; S R Wang; M E Yamamoto
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

View more
  22 in total

1.  Transport, cilia, and PKD: must we in (cyst) on interrelationships? Focus on "Increased Na+/H+ exchanger activity on the apical surface of a cilium-deficient cortical collecting duct principal cell model of polycystic kidney disease".

Authors:  Ellis D Avner; Alicia A McDonough; William E Sweeney
Journal:  Am J Physiol Cell Physiol       Date:  2012-03-07       Impact factor: 4.249

Review 2.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

3.  Novel treatments of autosomal dominant polycystic kidney disease.

Authors:  Rex L Mahnensmith
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

4.  Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.

Authors:  Irfana Soomro; Ying Sun; Zhai Li; Lonnette Diggs; Georgia Hatzivassiliou; Ajit G Thomas; Rana Rais; Seth J Parker; Barbara S Slusher; Alec C Kimmelman; Stefan Somlo; Edward Y Skolnik
Journal:  Nephrol Dial Transplant       Date:  2018-08-01       Impact factor: 5.992

5.  Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease.

Authors:  Yu-Shi Bao; Shi-Ping Na; Ping Zhang; Xi-Bei Jia; Rui-Chan Liu; Cheng-Yuan Yu; Su-Hong Mu; Ru-Juan Xie
Journal:  J Clin Immunol       Date:  2011-12-28       Impact factor: 8.317

6.  Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease.

Authors:  David S Snyder; Lukmanee Tradtrantip; Chenjuan Yao; Mark J Kurth; A S Verkman
Journal:  J Med Chem       Date:  2011-07-12       Impact factor: 7.446

Review 7.  Drug discovery for polycystic kidney disease.

Authors:  Ying Sun; Hong Zhou; Bao-xue Yang
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

Review 8.  Cilium, centrosome and cell cycle regulation in polycystic kidney disease.

Authors:  Kyung Lee; Lorenzo Battini; G Luca Gusella
Journal:  Biochim Biophys Acta       Date:  2011-03-02

Review 9.  CFTR inhibitors.

Authors:  Alan S Verkman; David Synder; Lukmanee Tradtrantip; Jay R Thiagarajah; Marc O Anderson
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Joost P H Drenth; Hedwig d'Agnolo; Niek F Casteleijn; Johan W de Fijter; Tom J Gevers; Peter Kappert; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Vicente E Torres; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2013-12-15       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.